EDS ECHO Event Series: Vascular Ehlers-Danlos-Syndrome (vEDS) –
A Comprehensive Conference on Care for Individuals with vEDS
July 30-31, 2021
Scientific Chair: Dr. Sherene Shalhub
Community and Healthcare Professionals Event
Join us for our EDS ECHO Summit Series: Vascular EDS (vEDS) virtual event, with leading expert presentations on care for individuals with vEDS. Join us as leading experts present the latest research, management, and scientific information on vEDS and comorbidities, including topics such as:
- Family planning, anticipating, and managing pregnancy complications
- Children with vEDS
- School adaptions
- Exercise with vEDS
- BP control and management of autonomic dysfunction
- Gastrointestinal abnormalities in vEDS
- Pulmonary abnormalities in vEDS
- Arterial pathology
Objectives for this event are as follows:
- To understand the genetics and biology of vascular EDS (vEDS)
- To understand the presentation and management of non-vascular, and vascular pathology in vascular EDS (vEDS)
- To understand the considerations of family planning and pregnancy in vascular EDS (vEDS)
9.25 CME/CEU/CU Credits are available for Healthcare Professionals to claim for sessions that are viewed LIVE.
Community Voices will feature lived experiences from those living with vEDS, and how they manage aspects of their EDS, and symptoms. If you would be interested in sharing your experiences on video, please complete this form.
The agenda can be viewed on the registration pages below.
The virtual conference will take place online via Zoom Webinar, from 10:40 am – 5:20 pm Eastern Time (US and Canada) on July 30, and from 10:40 am – 6:15 pm on July 31. If you have questions please email email@example.com.
(Please use the converter world time buddy to find the correct times in your location.)
In support of improving patient care, this activity has been planned and implemented by The Ehlers-Danlos Society and Project ECHO®. Project ECHO® is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
AMA Designation Statement
Project ECHO® designates this live activity for a maximum of 9.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Project ECHO®, in compliance with the ACCME Standards of Commercial Support, requires anyone who is in a position to control the content of an activity discloses all relevant financial relationships they have had within the last 12 months with a commercial interest related to the content of the activity. The Planners and Presenters of this activity disclose that they have no financial relationships with any commercial interest. Professor Lara Bloom, Stacey Simmonds, Sacha Aziz, Dr. Alan Hakim, Dr. Sherene Shalhub, Lauren Puryear, Duncan Baker, Neeti Ghali, Dr. Peter Byers, Dr. Glenda Sobey, Dr. Fleur Van Dijk, Lianne Barret, Dr. Siddarth Prakash, Katie Wright, Dr. Xavier Jeunemaitre, Dr. Enid Neptune, Dr. Jessica A. Zagory, Dr. Laura Pace, Dr. Satish Raj, Dr. Manjit Matharu, Dr. Melissa Russo, Dr. Shaine Morris, Jared Griffin, Dr. Rohith Jesudas, Dr. Sheila Coogan, Dr. John Ohman, Dr. Amani Politano, Dr. Daphne Fulton, Dr. Stephanie Wallace, Dr. Jessica Bos, Dr. Hal Dietz.
Thank You To Our Event Sponsors!
Aytu BioPharma is a specialty pharmaceutical company with a growing commercial portfolio of prescription therapeutics and consumer health products. The company’s primary prescription products treat attention deficit hyperactivity disorder (ADHD) and other common pediatric conditions. Aytu markets ADHD products Adzenys XR-ODT® (amphetamine) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING), Cotempla XR-ODT® (methylphenidate) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING), and Adzenys-ER® (amphetamine) extended-release oral suspension (see Full Prescribing Information, including Boxed WARNING). The company’s other pediatric products include Karbinal® ER (carbinoxamine maleate), an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions, and Poly-Vi-Flor® and Tri-Vi-Flor®, two complementary fluoride-based prescription vitamin product lines containing combinations of fluoride and vitamins in various formulations for infants and children with fluoride deficiency. The company’s evolution has been driven by strategic in-licensing, acquisition-based transactions and organic product growth. As Aytu continues this trajectory, the company is building a complimentary therapeutic development pipeline that will address significant unmet needs. For more information, please visit aytubio.com.
373 Inverness Parkway, Suite 206
Englewood, CO 80112 USA
Lipedema is a chronic medical condition characterized by asymmetric buildup of adipose tissue (fat) in the legs and arms that occurs almost exclusively in women. It is a common but underrecognized disorder. Lipedema may cause pain, swelling, and easy bruising and be accompanied by an unusual texture within the fat that can feel like rice, peas, or walnuts beneath the surface of the skin.
At the Lipedema Foundation, we support collaborative research that addresses the basic biology, genetics, and epidemiology of lipedema with a mission to define, diagnose and develop treatments.
Please visit our website lipedema.org to learn more about the Lipedema Foundation.
39 Lewis Street,
+1-203-489-2989 | firstname.lastname@example.org